499 related articles for article (PubMed ID: 33820908)
1. Diffuse large B-cell lymphoma: new targets and novel therapies.
Cheson BD; Nowakowski G; Salles G
Blood Cancer J; 2021 Apr; 11(4):68. PubMed ID: 33820908
[TBL] [Abstract][Full Text] [Related]
2. Tafasitamab Plus Lenalidomide Versus 3 Rituximab-Based Treatments for Non-Transplant Eligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Matching-Adjusted Indirect Comparison.
Cordoba R; Prawitz T; Westley T; Sharma A; Ambarkhane S; Kapetanakis V; Sabatelli L
Adv Ther; 2022 Jun; 39(6):2668-2687. PubMed ID: 35403948
[TBL] [Abstract][Full Text] [Related]
3. Treatment strategies for patients with diffuse large B-cell lymphoma.
Poletto S; Novo M; Paruzzo L; Frascione PMM; Vitolo U
Cancer Treat Rev; 2022 Nov; 110():102443. PubMed ID: 35933930
[TBL] [Abstract][Full Text] [Related]
4. An evaluation of polatuzumab vedotin for the treatment of patients with diffuse large B-cell lymphoma.
Walji M; Assouline S
Expert Rev Hematol; 2020 Sep; 13(9):933-942. PubMed ID: 32700586
[TBL] [Abstract][Full Text] [Related]
5. Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Harris LJ; Patel K; Martin M
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33202794
[TBL] [Abstract][Full Text] [Related]
6. Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab.
Amaya ML; Jimeno A; Kamdar M
Drugs Today (Barc); 2020 Apr; 56(4):287-294. PubMed ID: 32309823
[TBL] [Abstract][Full Text] [Related]
7. Polatuzumab Vedotin: a New Target for B Cell Malignancies.
Choi Y; Diefenbach CS
Curr Hematol Malig Rep; 2020 Apr; 15(2):125-129. PubMed ID: 32172360
[TBL] [Abstract][Full Text] [Related]
8. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.
Shah N; Chari A; Scott E; Mezzi K; Usmani SZ
Leukemia; 2020 Apr; 34(4):985-1005. PubMed ID: 32055000
[TBL] [Abstract][Full Text] [Related]
9. [Current status and future prospects of diffuse large B-cell lymphoma treatment].
Yamaguchi M
Rinsho Ketsueki; 2022; 63(9):1126-1134. PubMed ID: 36198538
[TBL] [Abstract][Full Text] [Related]
10. Challenges and Opportunities in the Management of Diffuse Large B-Cell Lymphoma in Older Patients.
Di M; Huntington SF; Olszewski AJ
Oncologist; 2021 Feb; 26(2):120-132. PubMed ID: 33230948
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Doraiswamy A; Shah MR; Bannerji R
Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641
[TBL] [Abstract][Full Text] [Related]
12. RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma.
Nowakowski GS; Yoon DH; Mondello P; Joffe E; Peters A; Fleury I; Greil R; Ku M; Marks R; Kim K; Zinzani PL; Trotman J; Sabatelli L; Waltl EE; Winderlich M; Sporchia A; Kurukulasuriya NC; Cordoba R; Hess G; Salles G
Ann Hematol; 2023 Jul; 102(7):1773-1787. PubMed ID: 37171597
[TBL] [Abstract][Full Text] [Related]
13. Polatuzumab vedotin combined with rituximab-bendamustine immediately before stem cell mobilization in relapsed diffuse large B-cell lymphoma.
Takakuwa T; Okayama Y; Nakamae H; Kuno M; Makuuchi Y; Harada N; Okamura H; Nishimoto M; Nakashima Y; Koh H; Hino M
Ann Hematol; 2022 Jul; 101(7):1609-1610. PubMed ID: 35218398
[No Abstract] [Full Text] [Related]
14. How to Sequence Therapies in Diffuse Large B-Cell Lymphoma Post-CAR-T Cell Failure.
Logue JM; Chavez JC
Curr Treat Options Oncol; 2021 Oct; 22(12):112. PubMed ID: 34697650
[TBL] [Abstract][Full Text] [Related]
15. Polatuzumab vedotin plus bendamustine and rituximab (Pola-BR) was effective for neurolymphomatosis in a patient with refractory diffuse large B-cell lymphoma.
Shinmura K; Okubo S; Kadota S; Nakayama H; Sakurai A; Kurosawa S; Ito C; Aisa Y; Nakazato T
Ann Hematol; 2023 Jan; 102(1):223-225. PubMed ID: 36394579
[No Abstract] [Full Text] [Related]
16. Economic evaluation of polatuzumab-bendamustine-rituximab
Calamia M; McBride A; Abraham I
J Med Econ; 2021 Nov; 24(sup1):14-24. PubMed ID: 34866523
[TBL] [Abstract][Full Text] [Related]
17. Polatuzumab vedotin, an anti-CD79b antibody-drug conjugate for the treatment of relapsed/refractory diffuse large B-cell lymphoma.
Camus V; Tilly H
Future Oncol; 2021 Jan; 17(2):127-135. PubMed ID: 32954807
[TBL] [Abstract][Full Text] [Related]
18. United we stand: Double targeting of CD79B and CD20 in diffuse large B-cell lymphoma.
Tarantelli C; Bertoni F
Br J Haematol; 2022 Oct; 199(2):169-170. PubMed ID: 35917107
[TBL] [Abstract][Full Text] [Related]
19. Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: An update.
Lakshman A; Kumar SK
Am J Hematol; 2022 Jan; 97(1):99-118. PubMed ID: 34661922
[TBL] [Abstract][Full Text] [Related]
20. Polatuzumab vedotin-based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience.
Wang YW; Tsai XC; Hou HA; Tien FM; Liu JH; Chou WC; Ko BS; Chen YW; Lin CC; Cheng CL; Lo MY; Lin YC; Lu LC; Wu SJ; Kuo SH; Hong RL; Huang TC; Yao M
Ann Hematol; 2022 Feb; 101(2):349-358. PubMed ID: 34766217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]